Back to Acceleration Radar
NUTXNutex Health Inc
Consumer Discretionary · Business Services · Small
$209.59+1.70%
As of 23 Oct 2026Mkt cap $1.3B
Stage 13
WAIT
Fundamentals
45.7/75
Technical
6.7/15
Independent
52.4/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +2.4%
- 3M
- +40.9%
- 6M
- +93.6%
- 1Y
- +83.4%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 8.3xHist median 9.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 5.2x
- FCF yield
- 19.4%
Quality
- ROIC
- 86.3%
- Operating margin
- 27.2%
- FCF margin
- 28.1%
- Current ratio
- 3.4x
Growth
- Revenue growth
- +82.4%Latest FY YoY
- Revenue CAGR
- +27.5%
- EPS CAGR
- —
- FCF CAGR
- +15.8%
Capital
- Share-count trend
- +23.8%3Y annualised
- Net cash
- $142M-0.6x OCF
Annual trend
- CAGR 2021–2025
- +27.5%
- Latest · 2025
- $1B
- YoY
- +82.4%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded